I Cannot Review Your Microbiome Test Results
Commercial microbiome testing currently has no validated clinical utility and should not be used to guide medical decisions. 1, 2
Why These Tests Are Not Clinically Useful
Lack of Evidence-Based Standards
The fundamental problem is that there are no established clinical standards for interpreting microbiome test results. While research has identified associations between the microbiome and various diseases, we lack:
- Validated reference ranges for what constitutes a "healthy" microbiome 3
- Standardized testing methodologies that produce comparable results across laboratories 4, 5
- Proven clinical interventions based on test results 2
- Evidence that testing improves patient outcomes (morbidity, mortality, or quality of life) 1
Critical Technical Limitations
Multiple technical issues make current commercial tests unreliable:
Contamination Problems: Low biomass samples (which many commercial tests use) are heavily contaminated by reagent DNA, dust, and cross-contamination. Without proper negative controls—which commercial tests rarely include—it's impossible to distinguish real bacterial signals from contamination 4
Methodological Variability: Different DNA extraction kits, sequencing methods (16S rRNA vs shotgun metagenomics), and computational pipelines produce dramatically different results from the same sample 4, 6. The choice of which bacterial gene region to sequence fundamentally changes which bacteria are detected 4
Instability of Results: Your microbiome composition varies significantly based on:
- Recent antibiotic use (effects lasting weeks to months) 4
- Diet changes (even short-term) 4
- Medications (proton pump inhibitors, other prescriptions) 4
- Sample collection and storage methods 4
- Time of day and recent bowel movements 6
This means a test result represents only a snapshot that may not reflect your typical microbiome state.
Regulatory Gaps
Commercial microbiome tests are largely unregulated and operate as direct-to-consumer products without FDA oversight or clinical validation 1, 3. Companies can make claims without demonstrating clinical utility or analytical validity.
Limited Exceptions
The only clinically validated microbiome-related intervention is fecal microbiota transplantation (FMT) for recurrent Clostridioides difficile infection, which cures up to 90% of cases 4. However, this doesn't require pre-treatment microbiome testing—the diagnosis is made through standard stool testing for C. difficile toxins.
Some research suggests dysbiosis testing may have future utility in IBS and IBD 7, but these remain investigational and are not ready for routine clinical use 1.
What To Do Instead
Focus on evidence-based clinical evaluation:
- Document specific symptoms, their timing, triggers, and severity
- Review medication history (especially antibiotics, PPIs, NSAIDs)
- Assess dietary patterns and recent changes
- Consider validated diagnostic tests for specific conditions (celiac serology, inflammatory markers, colonoscopy when indicated)
- Implement evidence-based dietary interventions (low FODMAP for IBS, Mediterranean diet for cardiovascular health) without needing microbiome testing 2
The Bottom Line
Microbiome science is promising but premature for clinical application 1, 2, 6. Current commercial tests waste healthcare resources and may lead to inappropriate interventions based on uninterpretable results. Until we have validated reference ranges, standardized methodologies, and evidence that testing changes outcomes, these tests should not influence clinical decisions 1, 3.
The field requires years of additional research to establish what constitutes clinically meaningful dysbiosis, which interventions effectively modify the microbiome, and whether such modifications improve patient outcomes 1, 2.